TREBON Powder for oral solution Ref.[49840] Active ingredients: Acetylcysteine

Source: Health Products Regulatory Authority (IE)  Publisher: UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A., 14th km National Road 1, GR-145 64 Kifissia, Greece

4.1. Therapeutic indications

Trebon is indicated in adults as a mucolytic therapy in chronic bronchitis and other respiratory conditions associated with thick mucus hypersecretion.

4.2. Posology and method of administration

Posology

In general the usual recommended dosage is: 600mg once daily.

The dosage may be increased according to the instructions of the treating doctor based on the assessment of treatment outcomes.

Duration of treatment

The duration of therapy is dependent on the nature and severity of the illness, and should be decided by the doctor.

Paediatric population

Children older than 2 years of age and adolescents

The safety and efficacy of Trebon is not established in children aged 2 years and older and adolescents (see section 4.4). Other products with lower strengths of acetylcysteine are more suitable for this age group.

Children under 2 years of age

Trebon is contraindicated in children aged under 2 years (see section 4.3).

Elderly

Limited data in patients over 65 years of age is available.

Renal and hepatic impairment

In patients with renal or hepatic impairment there is insufficient data on whether dosage adjustments are required. Renal and hepatic impairment can reduce clearance and increase acetylcysteine plasma levels which may result in an increase in adverse drug reactions due to drug accumulation (see section 5.2).

Method of administration

Dissolve the content of one sachet in half a glass of water. This produces a solution that should be consumed immediately.

4.9. Overdose

There have been no cases of toxic overdose observed with orally-dosed acetylcysteine. Oral doses of up to 500mg/kg of acetylcysteine were tolerated without toxic effects.

a) Symptoms of intoxication

The following symptoms have been reported after overdoses of intravenous acetylcysteine: anaphylactoid reaction, bronchospasm and gastro-intestinal symptoms such as nausea, vomiting and diarrhoea. Oral overdose may lead to gastrointestinal adverse effects, such as nausea, vomiting and diarrhoea.

b) Treatment for overdose

Treatment of overdose is to be symptomatic and supportive treatment as indicated by the patient’s clinical condition.

6.3. Shelf life

3 years.

After preparation, the solution should be used immediately.

6.4. Special precautions for storage

This medicinal product does not require any special temperature storage conditions.

Store in the original package in order to protect from moisture.

6.5. Nature and contents of container

Sachets consisting of paper, aluminum foil, and polyethylene.

Pack size: 10, 20 or 30 sachets.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.